Blogs

Following their ongoing commitment to provide patients with the latest treatment options, doctors at OHC are evaluating another new treatment option for patients diagnosed with acute myeloid leukemia (AML). This treatment is for AML patients who are... Read More

OHC’s David M. Waterhouse, MD, MPH, is leading a national clinical trial as the principal investigator to evaluate a new treatment option for patients whose advanced non-small cell lung cancer has not responded to chemotherapy or immunotherapy... Read More

At OHC, our cancer doctors want to be able to tell every patient their cancer is in remission, and for patients with pancreatic cancer, that is a special gift. While pancreatic cancer survival rates have been improving over the last several... Read More

OHC is leading the way in the fight against breast cancer by assessing every new OHC breast cancer patient against national guidelines that will determine if they should seek genetic testing for mutations. It’s important for patients to know this... Read More

OHC, the region’s leading cancer experts, has opened two new clinical trials to evaluate an expanded use of the ground-breaking treatment, chimeric antigen receptor T-cell therapy (CAR-T), making this life-changing treatment available to more... Read More

OHC is evaluating a new treatment option for triple negative breast cancer through its clinical trials program. The results of the trial may provide new hope for women diagnosed with this aggressive form of breast cancer. Triple-negative breast... Read More

New research has just been published showing promising results for patients with non-small cell lung cancer (NSCLC) five years after treatment. Historically, NSCLC has been universally considered a fatal disease. Patients with stage 4 NSCLC who were... Read More

OHC is a leader in the development of a promising new treatment that is being studied in a new clinical trial for adult acute myeloid leukemia (AML). AML is the most common type of acute leukemia in adults and can progress quickly if not treated... Read More

September is Ovarian Cancer Awareness Month. OHC is participating in a clinical trial that is evaluating rucaparib (a targeted drug) in combination with nivolumab (an immunotherapy drug) as a maintenance therapy in patients with newly diagnosed... Read More